Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (5025)	7/29/1998 5:21:00 PM
From: Vector1	Read Replies (2) \| Respond to of 6136

<<Not enough analysts to follow companies, and therefore one shouldn't invest in low-priced bargains>> What it means is that these stocks will trade like crap until they make tangible progress. Examples are positive clinical results in a late stage trial or even FDA approval folowed by surging sales. When they move they will move big and reward the investor. V1

To: scaram(o)uche who wrote (5025)	7/29/1998 7:37:00 PM
From: Peter Church	Read Replies (1) \| Respond to of 6136

I'm still wondering what will become of my call options after the divisional stock comes out. Do you know of any precedents? I imagine the employee stock options are something the company is seriously thinking about, but are the open market options in the same boat? No word from Investor Relations on this question yet.